Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7184MR)

This product GTTS-WQ7184MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7184MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2931MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ7991MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ9805MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ1634MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ5585MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ84MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ15255MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ4394MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-224818
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW